A U.S. study has revealed that regular low-dose aspirin use may protect adults with type 2 diabetes from potentially fatal complications.
The preliminary study found that taking low-dose aspirin can significantly reduce the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk for heart and vascular diseases.
اضافة اعلان
The research, to be presented at the 2025 American Heart Association Scientific Sessions, analyzed electronic health records of over 11,500 adults with type 2 diabetes over a ten-year period. To ensure accuracy, participants at risk of bleeding were excluded from the study.
Results showed significant differences between aspirin users and non-users:
Heart attack risk dropped to 42.4% for users versus 61.2% for non-users.
Stroke risk fell to 14.5% compared with 24.8%.
All-cause mortality decreased to 33% versus 50.7%.
The benefits were most pronounced in patients who took aspirin regularly and consistently, and improvements were evident regardless of blood sugar levels, although the effect was stronger in those with well-controlled glucose levels.
Dr. Alicia Kinat, the study’s lead researcher, commented that “the magnitude of the benefit was surprising,” while emphasizing that the study did not track bleeding events, which is crucial for a comprehensive safety assessment of aspirin use.
Dr. Amit Khera, who was not involved in the study, noted that “these findings raise important questions for future research,” stressing that “the decision to take aspirin should be made after a thorough discussion with a healthcare team, weighing potential benefits against known bleeding risks.”
Cardiovascular disease remains the leading cause of death among type 2 diabetes patients. Current American Heart Association guidelines do not recommend low-dose aspirin for primary prevention in type 2 diabetics without a prior history of heart disease.
Despite the significance of the findings, the study has limitations: it is observational rather than a randomized clinical trial, and reliance on medical records to track adherence may not fully reflect real-world use.
Ultimately, the decision to use low-dose aspirin as a preventive measure against cardiovascular disease in type 2 diabetes patients should be individualized and supervised by a healthcare professional, carefully balancing potential benefits and risks. (Medical Express)
